Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Biosion logo — Delivering breakthrough therapeutics to patients globally

Biosion

Delivering breakthrough therapeutics to patients globally

Founded 2017 China Nanjing, China 20 employees Series B Biopharma, Biotechnology

General Information

Company Name Biosion
Founded Year 2017
Location China Nanjing, China +3
Employees 20
Industries Biopharma, Biotechnology
Funding Stage Series B
Social

Get notified when Biosion moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Biosion

Biosion, operating under the name Boaoxin, is a China-based biotechnology company founded in 2017 with the slogan "Delivering breakthrough therapeutics to patients globally." The company focuses on developing antibody-based therapies for immune and oncologic diseases, utilizing its proprietary H³ antibody discovery, SynTracer™ HT-endocytosis, and Flexibody™ bispecific platforms. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma, with plans to advance additional assets into the clinic for oncology indications. In 23 April 2023, Biosion secured a CNY10.00K Series B investment from hmc ventures, Wang Huachun, and Ruiying Asset Management. The company has operations in the US, Australia, and China. For more details, visit www.biosion.com.

Taxonomy: R&D, antibody-based therapies, immune diseases, oncologic diseases, biologics, H³ antibody discovery, SynTracer™ HT-endocytosis, Flexibody™ bispecific platforms, clinical trials, atopic dermatitis, severe asthma, oncology indications, global operations, biotech company

No funding data available for Biosion yet.

Get notified when Biosion raises funding

Biosion Alternatives & Competitors

Biosion vs
Planet Biotechnology, Inc.
Planet Biotechnology, Inc.

Developing promising antibodies and receptor/ligand-Fc fusion proteins for the treatment and prevent...

Debt Financing
5 employees
Biotechnology, Health and Wellness
Biosion vs
Medarex
Medarex United States

Medarex is a biopharmaceutical company focused on the discovery, development, and potential commerci...

93 employees
Biotechnology
Biosion vs
Zymeworks Inc.
Zymeworks Inc. Canada

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.

IPO
264 employees
Biotechnology, Health and Wellness

FAQ About Biosion

Delivering breakthrough therapeutics to patients globally
Biosion was founded in 2017.
Biosion is headquartered in Nanjing, China.
Biosion operates in the following industries: Biopharma, Biotechnology.
Biosion has approximately 20 employees.
Top alternatives and competitors to Biosion include Planet Biotechnology, Inc., Medarex, Zymeworks Inc., Narval, Shanghai Junshi Biosciences Co Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biosion and Planet Biotechnology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Biosion and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy